Literature DB >> 30610063

Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.

Ioannis Parodis1,2, Alvaro Gomez3,2, Sharzad Emamikia3,2, Katerina Chatzidionysiou3,2.   

Abstract

Entities:  

Keywords:  belimumab; biologics; organ damage; systemic lupus erythematosus; treatment

Year:  2019        PMID： 30610063     DOI： 10.1136/annrheumdis-2018-214880

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.

Authors:  Ioannis Parodis; Alvaro Gomez; Julius Lindblom; Jun Weng Chow; Andrea Doria; Mariele Gatto
Journal:  Front Med (Lausanne)       Date:  2022-04-28

2.  Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.

Authors:  Ioannis Parodis; Petter Johansson; Alvaro Gomez; Sofia Soukka; Sharzad Emamikia; Katerina Chatzidionysiou
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 3.  B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools.

Authors:  Ioannis Parodis; Mariele Gatto; Christopher Sjöwall
Journal:  Front Med (Lausanne)       Date:  2022-08-30

4.  EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.

Authors:  Julius Lindblom; Alvaro Gomez; Alexander Borg; Sharzad Emamikia; Dimitris Ladakis; Joaquin Matilla; Martin Pehr; Flordelyn Cobar; Yvonne Enman; Emelie Heintz; Malin Regardt; Ioannis Parodis
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.